+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-10-26Number of Pages: 183

Human Vaccines Market (Vaccine Type - Conjugate, Recombinant, Inactivated, Combination, and Attenuated; Product - Pneumococcal, Influenza, Hepatitis, HPV, Meningococcal, Rotavirus, Measles, Typhoid, and Combination; Age Group - Pediatrics, Adolescents, Adults, and Geriatrics; Distribution Channel - Hospital Pharmacies and Drugstores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Human Vaccines Market: Snapshot

Vaccination has been promoted as a vital public health intervention across the globe for decades. According to the World Health Organization (WHO), vaccination has reduced the global burden of infectious disease to a great extent. An extremely low risk of serious and fatal side effects associated with vaccines and growing awareness regarding vaccination by various government and non-profit organizations are the key factors driving the human vaccines market.

The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. Extensive promotion and marketing strategies and favorable government support are likely to boost market growth.

Conjugates Dominate Human Vaccines Market by Type

On basis of vaccine type, the conjugate vaccines segment accounted for the majority share in the global human vaccines market in 2015. Prevnar, manufactured by Pfizer, Inc., is a conjugate vaccine, which generated a significant revenue of US$6.2 bn globally in 2015 alone. This is a key factor contributing to the dominance of conjugates in the human vaccine market. However, the growing preference for commercial brands available in the market is likely to drive the combination vaccines segment.

The pneumococcal segment accounted for the majority share in the global human vaccines market by product. A large number of products are commercially available in the market and the prevalence of pneumonia is high across several regions. These factors have been known to drive the pneumococcal segment.

By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Factors such as the high prevalence of pneumonia and polio among children across the world are likely to fuel this segment. On the other hand, adult vaccines are expected to expand at the highest CAGR from 2016 to 2024.

By distribution channel, the hospital pharmacies segment accounted for the lion’s share in the global human vaccines market. However, the drugstores segment is projected to expand at a considerable CAGR during the forecast period owing to a dramatically increasing vaccination rate in standalone pharmacies in the U.S.

 

human vaccines market

 

Strong Government Support Benefits Markets in APAC, LATAM, and Africa

North America was the dominant market for human vaccines in terms of revenue in 2015 owing to the growing demand for vaccination among adults and children. The market is also fueled by the increase in government efforts toward vaccination programs and the fact that most vaccines are available in the U.S.

Asia Pacific is expected to register the strongest growth in the market for human vaccines. Increasing government efforts toward immunization for various diseases such as polio, flu, rotavirus, and typhoid has been boosting the market. A massive population base is also likely to fuel market growth, especially in China and India. China is likely to dominate the Asia Pacific human vaccines market during the forecast period owing to a large population base and growing government support toward vaccination.

Brazil is likely to be the leading market for human vaccines in Latin America by 2024. A large population base, growing healthcare infrastructure, and a rise in subsidiaries for industry participants are the major factors boosting the human vaccines market in Brazil. GCC plays a significant role in the human vaccines market in the Middle East and Africa, as does South Africa. The market in Africa has been witnessing strong growth due to frequent outbreaks in the region, a rapid rise in vaccination programs, and increasing investments by major players.

Major players operating in the global human vaccines market include AstraZeneca, GlaxoSmithKline plc, Merck & Co. Inc., Pfizer, Inc., Sanofi, and Johnson & Johnson.

1. Preface
     1.1. Research Scope     
     1.2. Market Segmentation
     1.3. Research Objectives
     1.4. Key Questions Answered

2. Assumptions and Research Methodology
     2.1. Report Assumptions
     2.2. Acronyms Used
     2.3. Research Methodology

3. Executive Summary
     3.1. Global Human Vaccines Market Snapshot
     3.2. Market Opportunity Map

4. Market Overview
     4.1. Product Overview
     4.2. Key Industry Events
     4.3. Emerging Trend in Human Vaccines Market

5. Market Dynamics
     5.1. Drivers and Restraints Snapshot Analysis
     5.2. Drivers
     5.3. Restraints
     5.4. Opportunities
     5.5. Opportunity Analysis

6. Global Human Vaccines Market Analysis, by Vaccine Type
     6.1. Key Findings
     6.2. Introduction
     6.3. Conjugate
     6.4. Recombinant
     6.5. Conjugate Vaccines
     6.6. Inactivated
     6.7. Combination
     6.8. Attenuated
     6.9. Others
     6.10. Key Trends
     6.11. Market Attractiveness Analysis, by Vaccine Type, 2015

7. Global Human Vaccines Market Analysis, by Product
     7.1. Key Findings
     7.2. Introduction
     7.3. Pneumococcal
     7.4. Influenza
     7.5. Hepatitis
     7.6. HPV
     7.7. Meningococcal
     7.8. Rotavirus
     7.9. Measles and Rubella
     7.10. Typhoid
     7.11. Combination
     7.12. Others
     7.13. Key Trend Analysis

8. Global Human Vaccines Market Analysis, by Distribution Channel
     8.1. Key Findings
     8.2. Introduction
     8.3. Hospital Pharmacies
     8.4. Drugstores
     8.5. Others
     8.6. Key Trend Analysis
     8.7. Market Attractiveness Analysis

9. Global Human Vaccines Market Analysis, by Age Group
     9.1. Key Findings
     9.2. Introduction
     9.3. Pediatrics
     9.4. Adolescents
     9.5. Adults
     9.6. Geriatrics
     9.7. Key Trend Analysis
     9.8. Market Attractiveness Analysis

10. Global Human Vaccines Market Analysis, by Region
     10.1. North America
     10.2. Europe
     10.3. Asia Pacific
     10.4. Latin America
     10.5. Middle East & Africa

11. North America Human Vaccines Market Analysis
     11.1. North America Human Vaccines Market Size Forecast, By Country, 2016-2024
     11.2. North America Human Vaccines Market Size Forecast, By Product, 2016-2024
     11.3. North America Human Vaccines Market Size Forecast, By Vaccine Type, 2016-2024
     11.4. North America Human Vaccines Market Size Forecast, By Age Group, 2016-2024
     11.5. North America Human Vaccines Market Size Forecast, By Distribution Channel, 2016-2024
     11.6. North America Human Vaccines Market Attractiveness Analysis, 2016-2024

12. Europe Human Vaccines Market Analysis
     12.1. Europe Human Vaccines Market Size Forecast, By Country, 2016-2024
     12.2. Europe Human Vaccines Market Size Forecast, By Product, 2016-2024
     12.3. Europe Human Vaccines Market Size Forecast, By Vaccine Type, 2016-2024
     12.4. Europe Human Vaccines Market Size Forecast, By Age Group, 2016-2024
     12.5. Europe Human Vaccines Market Size Forecast, By Distribution Channel, 2016-2024
     12.6. Europe Human Vaccines Market Attractiveness Analysis, 2016-2024

13. Asia Pacific Human Vaccines Market Analysis
     13.1. Asia Pacific Human Vaccines Market Size Forecast, By Country, 2016-2024
     13.2. Asia Pacific Human Vaccines Market Size Forecast, By Product, 2016-2024
     13.3. Asia Pacific Human Vaccines Market Size Forecast, By Vaccine Type, 2016-2024
     13.4. Asia Pacific Human Vaccines Market Size Forecast, By Age Group, 2016-2024
     13.5. Asia Pacific Human Vaccines Market Size Forecast, By Distribution Channel, 2016-2024
     13.6. Asia Pacific Human Vaccines Market Attractiveness Analysis, 2016-2024

14. Latin America Human Vaccines Market Analysis
     14.1. Latin America Human Vaccines Market Size Forecast, By Country, 2016-2024
     14.2. Latin America Human Vaccines Market Size Forecast, By Product, 2016-2024
     14.3. Latin America Human Vaccines Market Size Forecast, By Vaccine Type, 2016-2024
     14.4. Latin America Human Vaccines Market Size Forecast, By Age Group, 2016-2024
     14.5. Latin America Human Vaccines Market Size Forecast, By Distribution Channel, 2016-2024
     14.6. Latin America Human Vaccines Market Attractiveness Analysis, 2016-2024

15. Middle East & Africa Human Vaccines Market Analysis
     15.1. Middle East & Africa Human Vaccines Market Size Forecast, By Country, 2016-2024
     15.2. Middle East & Africa Human Vaccines Market Size Forecast, By Product, 2016-2024
     15.3. Middle East & Africa Human Vaccines Market Size Forecast, By Vaccine Type, 2016-2024
     15.4. Middle East & Africa Human Vaccines Market Size Forecast, By Age Group, 2016-2024
     15.5. Middle East & Africa Human Vaccines Market Size Forecast, By Distribution Channel, 2016-2024
     15.6. Middle East & Africa Human Vaccines Market Attractiveness Analysis, 2016-2024

16. Competitive Landscape
     16.1. Human Vaccines Market Share Analysis By Company (2015)
     16.2. Competition Matrix

17. Company Profiles
     17.1. AstraZeneca
            17.1.1. Company Details
            17.1.2. Company Description
            17.1.3. Business Overview
            17.1.4. SWOT Analysis
            17.1.5. Financial Analysis
            17.1.6. Strategic Overview
     17.2. Bavarian Nordic
            17.2.1. Company Details
            17.2.2. Company Description
            17.2.3. Business Overview
            17.2.4. SWOT Analysis
            17.2.5. Financial Analysis
            17.2.6. Strategic Overview
     17.3. Bharat Biotech
            17.3.1. Company Details
            17.3.2. Company Description
            17.3.3. Business Overview
            17.3.4. SWOT Analysis
            17.3.5. Financial Analysis
            17.3.6. Strategic Overview
     17.4. CSL Limited
            17.4.1. Company Details
            17.4.2. Company Description
            17.4.3. Business Overview
            17.4.4. SWOT Analysis
            17.4.5. Financial Analysis
            17.4.6. Strategic Overview
     17.5. Emergent BioSolutions, Inc.
            17.5.1. Company Details
            17.5.2. Company Description
            17.5.3. Business Overview
            17.5.4. SWOT Analysis
            17.5.5. Financial Analysis
            17.5.6. Strategic Overview
     17.6. GlaxoSmithKline plc
            17.6.1. Company Details
            17.6.2. Company Description
            17.6.3. Business Overview
            17.6.4. SWOT Analysis
            17.6.5. Financial Analysis
            17.6.6. Strategic Overview
     17.7. Johnson & Johnson
            17.7.1. Company Details
            17.7.2. Company Description
            17.7.3. Business Overview
            17.7.4. SWOT Analysis
            17.7.5. Financial Analysis
            17.7.6. Strategic Overview
     17.8. Merck & Co., Inc.
            17.8.1. Company Details
            17.8.2. Company Description
            17.8.3. Business Overview
            17.8.4. SWOT Analysis
            17.8.5. Financial Analysis
            17.8.6. Strategic Overview
     17.9. Mymetics
            17.9.1. Company Details
            17.9.2. Company Description
            17.9.3. Business Overview
            17.9.4. SWOT Analysis
            17.9.5. Financial Analysis
            17.9.6. Strategic Overview
     17.10. Novartis AG
            17.10.1. Company Details
            17.10.2. Company Description
            17.10.3. Business Overview
            17.10.4. SWOT Analysis
            17.10.5. Financial Analysis
            17.10.6. Strategic Overview
     17.11. Pfizer, Inc.
            17.11.1. Company Details
            17.11.2. Company Description
            17.11.3. Business Overview
            17.11.4. SWOT Analysis
            17.11.5. Financial Analysis
            17.11.6. Strategic Overview
     17.12. Sanofi
            17.12.1. Company Details
            17.12.2. Company Description
            17.12.3. Business Overview
            17.12.4. SWOT Analysis
            17.12.5. Financial Analysis
            17.12.6. Strategic Overview
     17.13. Shenzhen Kangtai Biological Products Co., Ltd.
            17.13.1. Company Details
            17.13.2. Company Description
            17.13.3. Business Overview
            17.13.4. SWOT Analysis
            17.13.5. Financial Analysis
            17.13.6. Strategic Overview
     17.14. Takeda Pharmaceutical Company Limited.
            17.14.1. Company Details
            17.14.2. Company Description
            17.14.3. Business Overview
            17.14.4. SWOT Analysis
            17.14.5. Financial Analysis
            17.14.6. Strategic Overview

List of Figures

FIG. 1 Global Human Vaccines Market Value Share Analysis, by Vaccine Type, 2015 and 2024
FIG. 2 Global Conjugate Market Revenue (US$ Mn), 2014–2024
FIG. 3 Global Recombinant Market Revenue (US$ Mn), 2014–2024
FIG. 4 Global Inactivated Market Revenue (US$ Mn), 2014–2024
FIG. 5 Global Combination Market Revenue (US$ Mn), 2014–2024
FIG. 6 Global Attenuated Market Revenue (US$ Mn), 2014–2024
FIG. 7 Global Others Market Revenue (US$ Mn), 2014–2024
FIG. 8 Human Vaccines Market Attractiveness Analysis, by Vaccine Type, 2015
FIG. 9 Global Human Vaccines Market Value Share Analysis, by Product, 2015 and 2024
FIG. 10 Global Pneumococcal Market Revenue (US$ Mn), 2014–2024
FIG. 11 Global Influenza Market Revenue (US$ Mn), 2014–2024
FIG. 12 Global Hepatitis Market Revenue (US$ Mn), 2014–2024
FIG. 13 Global HPV Market Revenue (US$ Mn), 2014–2024
FIG. 14 Global Meningococcal Market Revenue (US$ Mn), 2014–2024
FIG. 15 Global Rotavirus Market Revenue (US$ Mn), 2014–2024
FIG. 16 Global Measles and Rubella Market Revenue (US$ Mn), 2014–2024
FIG. 17 Global Typhoid Market Revenue (US$ Mn), 2014–2024
FIG. 18 Global Combination Market Revenue (US$ Mn), 2014–2024
FIG. 19 Global Others Market Revenue (US$ Mn), 2014–2024
FIG. 20 Human Vaccines Market Attractiveness Analysis, by Product, 2015
FIG. 21 Global Human Vaccines Market Value Share Analysis, by Distribution Channel, 2015 and 2024
FIG. 22 Global Hospital Pharmacies Market Revenue (US$ Mn), 2014–2024
FIG. 23 Global Drugstores Market Revenue (US$ Mn), 2014–2024
FIG. 24 Global others Market Revenue (US$ Mn), 2014–2024
FIG. 25 Human Vaccines Market Attractiveness Analysis, by Distribution Channel, 2015
FIG. 26 Global Human Vaccines Market Value Share Analysis, by Age Group, 2015 and 2024
FIG. 27 Global Pediatrics Market Revenue (US$ Mn), 2014–2024
FIG. 28 Global Adolescents Market Revenue (US$ Mn), 2014–2024
FIG. 29 Global Adults Market Revenue (US$ Mn), 2014–2024
FIG. 30 Global Geriatrics Market Revenue (US$ Mn), 2014–2024
FIG. 31 Human Vaccines Market Attractiveness Analysis, by Age Group, 2015
FIG. 32 North America Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 33 Europe Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 34 APAC Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 35 Latin America Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 36 MEA Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 37 Global Human Vaccines Market Attractiveness Analysis, by Region
FIG. 38 China Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 39 Japan Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 40 ASEAN Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 41 Rest of APAC Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 42 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Country
FIG. 43 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Product
FIG. 44 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Vaccine Type
FIG. 45 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Age Group
FIG. 46 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Distribution Channel
FIG. 47 U.S. Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 48 Canada Human Vaccines Market Size (US$ Mn) Forecast, 2016–202
FIG. 49 North America Human Vaccines Market Attractiveness Analysis, by Country
FIG. 50 North America Human Vaccines Market Attractiveness Analysis, by Product
FIG. 51 North America Human Vaccines Market Attractiveness Analysis, by Vaccine Type
FIG. 52 North America Human Vaccines Market Attractiveness Analysis, by Age Group
FIG. 53 North America Human Vaccines Market Attractiveness Analysis, by Distribution Channel
FIG. 54 Germany Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 55 France Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 56 U.K. Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 57 Italy Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 58 Spain Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 59 Rest of Europe Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 60 Europe Human Vaccines Market Attractiveness Analysis, by Country
FIG. 61 Europe Human Vaccines Market Attractiveness Analysis, by Product
FIG. 62 Europe Human Vaccines Market Attractiveness Analysis, by Vaccine Type
FIG. 63 Europe Human Vaccines Market Attractiveness Analysis, by Age Group
FIG. 64 Europe Human Vaccines Market Attractiveness Analysis, by Distribution Channel
FIG. 65 Brazil Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 66 Mexico Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 67 Rest of LATAM Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 68 Latin America Human Vaccines Market Attractiveness Analysis, by Country
FIG. 69 Latin America Human Vaccines Market Attractiveness Analysis, by Product
FIG. 70 Latin America Human Vaccines Market Attractiveness Analysis, by Vaccine Type
FIG. 71 Latin America Human Vaccines Market Attractiveness Analysis, by Age Group
FIG. 72 Latin America Human Vaccines Market Attractiveness Analysis, by Distribution Channel
FIG. 73 GCC Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 74 South Africa Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 75 Rest of MEA Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 76 MEA Human Vaccines Market Attractiveness Analysis, by Country
FIG. 77 MEA Human Vaccines Market Attractiveness Analysis, by Product
FIG. 78 MEA Human Vaccines Market Attractiveness Analysis, by Vaccine Type
FIG. 79 MEA Human Vaccines Market Attractiveness Analysis, by Age Group
FIG. 80 MEA Human Vaccines Market Attractiveness Analysis, by Distribution Channel
FIG. 81 Human Vaccine Market Share Analysis, by Company (2015)

List of Tables

TABLE 1 Global Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2016–2024
TABLE 2 Global Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2016–2024
TABLE 3 Global Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 4 Global Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2016–2024
TABLE 5 Global Human Vaccines Market Size (US$ Mn) Forecast, by Region, 2016–2024
TABLE 6 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 7 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2016–2024
TABLE 8 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2016–2024
TABLE 9 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2016–2024
TABLE 10 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 11 North America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 12 North America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2016–2024
TABLE 13 North America Human Vaccines Market Size (US$) Forecast, by Vaccine Type, 2016–2024
TABLE 14 North America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2016–2024
TABLE 15 North America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 16 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 17 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2016–2024
TABLE 18 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2016–2024
TABLE 19 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2016–2024
TABLE 20 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 21 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 22 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2016–2024
TABLE 23 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2016–2024
TABLE 24 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2016–2024
TABLE 25 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 26 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 27 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2016–2024
TABLE 28 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2016–2024
TABLE 29 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2016–2024
TABLE 30 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024

Human Vaccines Market: Scope and Methodology

This report provides in-depth region wise and country wise analysis of the human vaccines market. Stakeholders of this report include manufacturers of human vaccines products, raw material suppliers, vaccine processing companies, and new players planning to enter the market.

The report provides qualitative and quantitative analysis of the global human vaccines market. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information. Quantitative analysis includes market share held by companies in 2015, market size, and forecast for the global human vaccines market in major countries globally such as the U.S., Canada, Germany, France, United Kingdom, Italy, Spain, Japan, China, Brazil, Mexico, South Africa and GCC countries. Market revenue is provided in terms of US$ Mn from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 for all the segments, considering 2015 as the base year. The executive summary of the report provides a snapshot of the human vaccines with information on leading segments, country wise market information with respect to the market size, growth rate (CAGR %), and growth factors.

The market overview section comprises impact factors such as drivers, restraints, and opportunities for the global human vaccines market. These factors would aid the stakeholders in establishing a strong foothold in the global human vaccines market. Furthermore, the market overview section comprises key industry events, product overview, market attractiveness analysis and emerging trend in the human vaccines. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments and country wise to identify the most attractive market. Market share analysis is also provided in the competitive landscape section of the report for the year 2015 in terms of value (%).

Human Vaccines Market: Segmentation

The human vaccines market has been segmented as vaccine type, products, age group, distribution channel and geography. Based on vaccine type, the market has been segmented into conjugate, recombinant, inactivated, combination, attenuated, and others. Likewise, on basis of product the market has been categorized into pneumococcal, influenza, hepatitis, HPV, meningococcal, rotavirus, measles and mumps, typhoid, combination and others. By age group the market is categorized into pediatrics, adolescent, adult and geriatrics. Hospital pharmacies, drugstores and others are included into the market by distribution channel

Geographically, the human vaccines market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, analysis for the major countries comprising U.S. Canada, Germany, U.K., France, Italy, Spain, Japan, China, Brazil, Mexico, and South Africa have also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the human vaccines market in various regions has been provided in this section. This report also includes various ups and downs about particular country or geography that has impacted the overall market globally.

Human Vaccines Market: Competitive Landscape

The report provides a detailed outline/blueprint of the human vaccines market globally that will assist new companies in establishing their presence and market players in expanding their market share in the market. The report concludes with the company profile section which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include Major players operating in the global human vaccines market include AstraZeneca, GlaxoSmithKline plc, Merck & Co. Inc., Pfizer, Inc., Sanofi and Johnson & Johnson among others.

The global human vaccines market is segmented into the following categories:

Global human Vaccines Market, by Vaccine Type

  • Conjugate
  • Recombinant
  • Inactivated
  • Combination
  • Attenuated
  • Others

Global Human Vaccines Market, by Product

  • Pneumococcal
  • Influenza
  • Hepatitis
  • HPV
  • Meningococcal
  • Rotavirus
  • Measles and Mumps
  • Typhoid
  • Combination
  • Others

Global Human Vaccines Market, by Age Group

  • Pediatrics
  • Adolescents
  • Adults
  • Geriatrics

Global Human Vaccines Market, by Distribution Channel

  • Hospital Pharmacies
  • Drugstores
  • Others

Global Human Vaccines Market, by Geography

  • North America
    • U.S.
    • Canada
    • Europe
  • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)
    • Japan
    • China
    • ASEAN
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa (MEA)
    • GCC
    • South Africa
    • Rest of MEA


 
 
Back To Top